Respiratory Difficulties in Children With Underlying Asthma During Immunotherapy for High-risk Neuroblastoma

J Pediatr Hematol Oncol. 2017 Nov;39(8):e450-e453. doi: 10.1097/MPH.0000000000000782.

Abstract

Treatment of high-risk neuroblastoma now includes antibody based antitumor immunotherapy as part of standard care. Although this therapy has resulted in dramatic improvements in survival, it is associated with significant side effects. Children with underlying respiratory issues, and in particular asthma, may be more susceptible to immunotherapy associated respiratory compromise and pulmonary complications. Early routine involvement of pulmonology care is warranted for these patients in an effort to allow maximal delivery of immunotherapy and minimize acute and long-term complications.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Asthma / complications*
  • Child, Preschool
  • Female
  • Humans
  • Immunotherapy
  • Male
  • Neuroblastoma / complications*
  • Neuroblastoma / diagnosis
  • Neuroblastoma / therapy
  • Pulmonary Fibrosis / diagnosis
  • Pulmonary Fibrosis / etiology
  • Pulmonary Fibrosis / physiopathology
  • Radiography, Thoracic
  • Respiratory Function Tests
  • Respiratory Insufficiency / diagnosis*
  • Respiratory Insufficiency / etiology*
  • Tomography, X-Ray Computed

Substances

  • Antibodies, Monoclonal